DDInter1259 DDInter1082
Nalidixic acid is a synthetic 1,8-naphthyridine antimicrobial agent with a limited bacteriocidal spectrum. It is an inhibitor of the A subunit of bacterial DNA gyrase.
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM). It is sold by Sanofi-Aventis under the brand name Adlyxin in the US and Lyxumia in the EU. Adlyxin recieved FDA approval July 28, 2016.
Nalidixic acid {u} (Compound) resembles {v} (Compound) Norfloxacin
Nalidixic acid {u} (Compound) resembles {v} (Compound) Rosoxacin
Nalidixic acid {u} (Compound) binds {v} (Gene) TDO2
Nalidixic acid {u} (Compound) upregulates {v} (Gene) HERC6
Nalidixic acid {u} (Compound) downregulates {v} (Gene) DHRS7
Nalidixic acid {u} (Compound) causes {v} (Side Effect) Erythema multiforme
Nalidixic acid (Compound) resembles Norfloxacin (Compound)
Nalidixic acid (Compound) resembles Rosoxacin (Compound)
Nalidixic acid (Compound) binds TDO2 (Gene)
Nalidixic acid (Compound) upregulates HERC6 (Gene)
Nalidixic acid (Compound) downregulates DHRS7 (Gene)
Nalidixic acid (Compound) causes Erythema multiforme (Side Effect)